Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study

@article{Hofman2020ProstatespecificMA,
  title={Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study},
  author={Michael S. Hofman and Nathan L Lawrentschuk and Roslyn Jane Francis and Colin Tang and Ian Vela and Paul A Thomas and Natalie K Rutherford and Jarad Martin and Mark Frydenberg and Ramdave Shakher and Lih-Ming Wong and Kim Taubman and Sze Ting Lee and Edward C. Hsiao and Paul J. Roach and Michelle K Nottage and Ian D. Kirkwood and Dickon Hayne and Emma Link and Petra Marusic and Anetta Matera and Alan Herschtal and Amir Iravani and Rodney J. Hicks and Scott G. Williams and Declan G. Murphy},
  journal={The Lancet},
  year={2020},
  volume={395},
  pages={1208-1216}
}

Cost-Effectiveness Analysis of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) for the Primary Staging of Prostate Cancer in Australia

A cost-utility analysis of PSMA PET/CT compared with conventional imaging for patients with newly diagnosed, intermediate-risk or high-risk primary prostate cancer in Australia found the results were most sensitive to the time horizon, and the initial treatments received by patients diagnosed with metastatic cancer.

Dual-Tracer Positron-Emission Tomography Using Prostate-Specific Membrane Antigen and Fluorodeoxyglucose for Staging of Prostate Cancer: A Systematic Review

FDG after PSMA PET improved the detection of metastases from 65% to 73% in high-risk early castration-resistant PCa with negative conventional imaging (M0), and Dual-tracer PET for PCa may assist in characterising high- risk disease during primary staging and restaging.

Prostate-specific membrane antigen PET/computed tomography for staging prostate cancer.

PSMA PET/CT has emerged as a new standard in primary staging of PCa, and incorporation into international clinical guidelines is anticipated within the next few years.

High Accuracy of PSMA PET in Initial Staging of High-Risk Prostate Cancer.

The findings of this study demonstrate that PSMA PET/CT is a viable replacement for conventional imaging for prostate cancer and suggest that PSma PET has value for incorporation into standard clinical management guidelines for the initial staging of prostate cancer.

PSMA PET/CT guided intensification of therapy in patients at risk of advanced prostate cancer (PATRON): a pragmatic phase III randomized controlled trial

This study will help create level 1 evidence needed to demonstrate whether or not intensification of radiotherapy or surgery based on PSMA PET findings improves outcomes of patients at risk of advanced prostate cancer in a manner that is cost-effective.

Detection of prostate cancer with 18F-DCFPyL PET/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible? The DeTeCT trial

An accurate per-patient detection and localisation of PCa-localisation on 18F-DCFPyL-PET/CT with the RARP specimens, potentially allows for accurate PSMA-targeted biopsy.
...

References

SHOWING 1-10 OF 29 REFERENCES

Prospective Validation of Gallium-68 PSMA-PET/CT in Primary Staging of Prostate Cancer Patients.

In newly diagnosed prostate cancer patients with >10% MSKCC risk of lymph node involvement, 68Ga-PSMA-PET/CT detects lymph node metastases with high specificity and moderate sensitivity; this leads to change of management in 12.6% of patients.

Impact of 68Ga-PSMA-11 PET staging on clinical decision-making in patients with intermediate or high-risk prostate cancer

Information from 68Ga-PSMA-11 PET staging has the potential to change the management in more than a fourth of the patients who underwent PET staging for their intermediate to high-risk prostate cancer.

A prospective randomized multicentre study of the impact of gallium‐68 prostate‐specific membrane antigen (PSMA) PET/CT imaging for staging high‐risk prostate cancer prior to curative‐intent surgery or radiotherapy (proPSMA study): clinical trial protocol

Prostate‐specific membrane antigen (PSMA) positron‐emission tomography (PET)/computed tomographic (CT) is a new whole‐body scanning technique that enables visualization of PCa with high contrast and there are economic benefits if PSMA‐PET/CT is incorporated into the management algorithm.

Impact of 68Ga-PSMA-PET imaging on target volume definition and guidelines in radiation oncology - a patterns of failure analysis in patients with primary diagnosis of prostate cancer

68Ga-PSMA-PET-imaging proves to be a valuable asset for patients and physicians for primary diagnosis and treatment planning and trusting the RTOG consensus for CTV delineation would have led to up to 35.7% of all LNs not to be included in the clinical radiation volume, which might have resulted in insufficient radiation dose coverage.

Risk of metastatic disease on 68 Ga-PSMA PET/CT scan for primary staging of 1253 men at the diagnosis of prostate cancer.

The results support the use of 68Ga-PSMA PET/CT for primary staging of prostate cancer and increasing PSA level, ISUP grade and radiological staging with mpMRI were all statistically significant prognostic factors for metastasis on both univariate and multivariate analysis.

The Impact of 68Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study

The potential clinical value of 68Ga-PSMA PET/CT in management of prostate cancer is demonstrated and may influence planned clinical management in a high proportion of patients with prostate cancer.

Potential Impact of 68Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer

To determine how often definitive RT planning based on standard target volumes covers 68Ga-PSMA-11 PET/CT–defined disease and to assess the potential impact of 68 Ga-PSma-11PET/CT on definitiveRT planning, a post hoc analysis of an intention-to-treat population of 73 patients with localized PCa without prior local therapy was conducted.